Putting buybacks on hold, Pfizer’s CEO is plotting a string of important PhII deals in the year ahead. You’ve been alerted
Pfizer shares took a beating on Tuesday, dropping 5% as investors found out that the pharma giant fell short on revenue projections and wouldn’t be riding to the rescue with their usual campaign of buybacks.
So what gives? Buybacks have been part of the culture at the company for years.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.